SynthesisOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2010
Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review.
Synthesis in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials.Journal of bone and mineral metabolism · 2014Pooled it
- Zinc supplementation improves bone density in patients with thalassemia: a double-blind, randomized, placebo-controlled trial.The American journal of clinical nutrition · 2013Trial
- Romosozumab for the treatment of thalassemia-associated osteoporosis in two female patients.JBMR plus · 2026Article
- Evaluation of Children and Adolescents with Thalassemia Major in Terms of Osteoporosis: A Single-Centre Experience.Journal of clinical medicine · 2025Article
- Using bone mineral apparent density for BMD adjustment in chronic diseases: Thalassemia an example.Caspian journal of internal medicine · 2024Article
- Alterations of panoramic radiomorphometric indices in children and adolescents with beta-thalassemia major: A fractal analysis study.Medicina oral, patologia oral y cirugia bucal · 2022Article
- The role of using different reference population in the prevalence of low BMD in the thalassemia patients.Journal of diabetes and metabolic disorders · 2020Article
- Evaluation of osseous changes in dental panoramic radiography of thalassemia patients using mandibular indexes and fractal size analysis.Oral radiology · 2020Article
- Administration of Intravenous Zoledronic Acid Every 3 Months vs. Annually in β-thalassemia Patients with Low Bone Mineral Density: a Retrospective Comparison of Efficacy.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2018Article
- Osteoporosis in young adults: pathophysiology, diagnosis, and management.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2012Review
- Past, present & future scenario of thalassaemic care & control in India.The Indian journal of medical research · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledZoledronate is a promising bisphosphonate that improves the bone mineral density by 0.69 standard deviations in thalassemia-induced osteoporosis, but the entire range of its actions and side effects is currently not fully understood.
introductionZoledronate is a promising bisphosphonate for the treatment of thalassemia-induced osteoporosis; however, a quantitative summary of its beneficial effect and its effects on the markers of bone turnover are not established.
methodsWe conducted a meta-analysis of the published randomized controlled trials using standardized mean difference and a random effects model for improvement in bone mineral density (BMD). We also conducted a systematic review for the influence of zoledronate on markers of bone turnover and bone pain.
resultsWe found that zoledronate improves the baseline BMD by 0.69 (95% confidence interval 0.47-0.90) standard deviations-an effect that was more pronounced when BMD was measured at the lumbar spine. However, the mechanistic interpretations of the effects on the markers of bone turnover are not completely clear.
conclusionSufficient evidence exists to demonstrate that 4 mg zoledronate given every 3 months markedly improves the BMD; however, more qualitative and quantitative evidence is required to understand the mechanisms of its action and the potential side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.